If you have been reading about triple agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Bupropion, formerly called amfebutamone, and sold under the brand name Wellbutrin among others, is an atypical antidepressant that is indicated in the treatment of major depressive disorder and seasonal affective disorder and to support smoking cessation. It is a norepinephrine–dopamine reuptake inhibitor (NDRI). Some evidence-based guidelines support first-line use. It is also popular as an add-on medication in the cases of "incomplete response" to the first-line selective serotonin reuptake inhibitor (SSRI) antidepressant. Bupropion has several features that distinguish it from other antidepressants: it does not usually cause sexual dysfunction, it is not associated with weight gain or sleepiness, and it is more effective than SSRIs at improving symptoms of hypersomnia and fatigue. Bupropion, particularly the immediate-release formulation, carries a higher risk of seizure than many other antidepressants; hence, caution is recommended in patients with a history of seizure disorder. The medication is taken by mouth. Common adverse effects of bupropion with the greatest difference from placebo are dry mouth, nausea, constipation, insomnia, anxiety, tremor, and excessive sweating. Raised blood pressure is notable. Rare but serious side effects include seizures, liver toxicity, psychosis, and risk of overdose. Bupropion use during pregnancy may be associated with increased likelihood of congenital heart defects. Bupropion acts as a norepinephrine–dopamine reuptake inhibitor (NDRI) and a nicotinic receptor antagonist.
The cooperative movement in India plays a crucial role in the dairy, agricultural, banking, and housing sectors. The history of cooperatives in India is more than a hundred years old, developing rapidly after Indian independence. As of 1 January 2026, over 848,000 cooperatives are active, according to the information available on the National Cooperative Database. Many cooperative societies, particularly in rural areas, increase political participation and are used as a stepping stone by aspiring politicians.
=== Ediya === Ediya is a mid-priced coffee chain, containing around 1,800 stores in South Korea since 2016. Founded in 2001, it is run by CEO Moon Chang-ki. In 2019, Ediya Coffee launched collaborated product with Kakao Friends (Kakaotalk; which is the famous Korean's communicating message app. It also has unique emoticons and those calls Kakao Friends). Collaboration In 2019, Ediya Coffee collaborated with Kakao Friends which are the representative characters of KakaoTalk company. The Kakao Friends are very popular because of its unique character cuteness feature and there's also Kakao Friends store where they sell character goods (accessories, dolls, golf wares, even the electronic products). With this popularity, Ediya coffee collaboration with Kakao Friends was successfully done. In March 2018, for the Spring signature drinks, Ediya Coffee launched 'Peach Blossom Latte', 'Peach Blossom Tea'. The following May, they released nine types of MD (character tumbler, water bottle, juice cup, straws etc.). The price range of MD's are from 1100 KRW to 12900 KRW(0.89 to 10.46 USD). Also released new drinks in the following year, in 2019 Ediya Coffee released three mini cakes that embody the appearance of the most popular characters (Apeach, Ryan, and Tube). Each of the cakes has different flavors depending on the character. Each cake costs 3500 KRW, which is 2.84 USD. The cakes that go well with coffee have drawn fervent responses from consumers.
Sources: en.wikipedia.org
Recent research has shown that commercially available UVA LEDs (365 nm) are already effective disinfection and sterilization devices. UV-C wavelengths were obtained in laboratories using aluminium nitride (210 nm), boron nitride (215 nm) and diamond (235 nm).
==== Companion of the Order of St Michael and St George (CMG) ==== Jennifer Elizabeth Anderson, Director, Consular and Crisis, Foreign, Commonwealth and Development Office. For services to British Foreign Policy and to British Nationals Overseas. Zamir Nicholas Catasaras, Director General for Russia and Ukraine, Cabinet Office. For services to British Foreign Policy. Roger James Coventry, Criminal Justice Adviser. For services to Justice and Stability overseas. Colin Mark Evans, Director General, Foreign, Commonwealth and Development Office. For services to National Security. Dr Fiona Hill, Senior Fellow, Brookings Institution, Washington D.C., United States of America. For services to International Relations. Dr Rurik Miles Marsden, , Development Director, British Embassy Yangon, Myanmar. For services to International Development. Susanna Mary Davies Moorehead, lately Chair, Development Assistance Committee, The Organisation for Economic Co-operation and Development (OECD). For services to International Development and Diplomacy. Jane Anne Nelson, Director, Corporate Responsibility Initiative, Kennedy School of Government, Harvard University, United States of America. For services to Business and to Sustainability. Dr Sara Pantuliano, Chief Executive, ODI. For services to Peacebuilding, to Humanitarian Assistance and to International Development. Simon Penny, lately H.M. Trade Commissioner for the Middle East and Pakistan and H.M. Consul General to Dubai and the Northern Emirates. For services to International Trade and Investment.
=== Cell Biology and Virology === Organised into subprograms including Eukaryotic Microbiology, Tumor Cell Biology, Virology, and Mammalian Cell Structure/Differentiation, this program studies cellular functions across organisms. Research areas include tumor-virus associations, host-pathogen signaling, gene therapy, and vaccine development.
Sources: en.wikipedia.org
=== Copulation === Copulation begins as the males use their chelicerae to rapidly move back and forth across the female's ventral body surface. This is an attempt to grab hold of the female's body and mount onto their epigyne. For some males, it can take up to 100 attempts to properly mount. Once mounted, the males pull the females closer to them resulting in rotation of the female opisthosoma from a horizontal to vertical position. At this point, the male is able to insert his pedipalps into the genital cavity of the female. During the multiple insertions, the male pedipalps are twisted into different motions in a synchronous fashion with the procursi being inserted deeply into the female genital cavity to release sperm into the uterus externus. As the coupling duration lengthens, the amount of palpal insertions decreases. The duration of copulation is dependent upon whether or not the female P. phalangioides have previously mated with any males. If the females have mated, second males are only allowed to engage in copulation for a few minutes. On the other hand, first males are able to copulate for anywhere between 16 and 122 minutes. Once the mating has finished, the females often act aggressively towards the males in an attempt to drive them off.
=== Media coverage === During the first few months of the COVID-19 pandemic in 2020, Chinese food markets were heavily criticized in media outlets as a potential source for the virus. Media reports urging for permanent blanket bans on all such markets, as opposed to solely live animal markets or wildlife markets, have been criticized for undermining infection control needs to be specific about wildlife markets and distracting public attention from local public health threats. Some Western media portrayed food markets without distinguishing between general food markets, live animal markets, and wildlife markets, using montages of explicit images from different markets across Asia without identifying locations. These depictions have been criticized by other journalists and anthropologists as sensationalist, exaggerated, Orientalist, and fueling Sinophobia and "Chinese otherness". Before 2020, most English speakers had never heard the term "wet market". Some coverage presented it as the local name for the Huanan market; NPR described the market as "known in the region as a 'wet market'". The market's Chinese name, 华南海鲜批发市场, identifies it as a seafood wholesale market; with more than 1,000 stalls across roughly 50,000 square metres, it was the largest seafood wholesale market in central China. Its main goods were crab, shrimp and striped bass, with wildlife sold in a separate section. Critics also argued that the word "wet" itself evokes unhygienic conditions.
William Turner's Historia Avium (History of Birds), published at Cologne in 1544, was an early ornithological work from England. He noted the commonness of kites in English cities where they snatched food out of the hands of children. He included folk beliefs such as those of anglers. Anglers believed that the osprey emptied their fishponds and would kill them, mixing the flesh of the osprey into their fish bait. Turner's work reflected the violent times in which he lived, and stands in contrast to later works such as Gilbert White's 1789 The Natural History and Antiquities of Selborne which were written in a tranquil era. In the 17th century, Francis Willughby (1635–1672) and John Ray (1627–1705) created the first major system of bird classification that was based on function and morphology rather than on form or behaviour. Willughby's Ornithologiae libri tres (1676) completed by John Ray is sometimes considered to mark the beginning of scientific ornithology. Ray also worked on Ornithologia, which was published posthumously in 1713 as Synopsis methodica avium et piscium. The earliest list of British birds, Pinax Rerum Naturalium Britannicarum, was written by Christopher Merrett in 1667, but authors such as John Ray considered it of little value. Ray did, however, value the expertise of the naturalist Sir Thomas Browne (1605–1682), who not only answered his queries on ornithological identification and nomenclature, but also those of Willoughby and Merrett in letter correspondence.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.